CD1C and melanoma: Analysis of correlation between CD1c+CD14+ frequencies and progression-free survival (PFS) for responding melanoma patients showed that high CD1c+CD14+ frequencies in the vaccine correlate with shorter PFS (R2 = 0.9570, p = 0.0038, n = 5) (Figure S1B).